Then, the GSE93157 database, including NSCLC patients receiving PD1-targeting antibodies pembrolizumab or nivolumab, and the IMvigor210 database, including metastatic urothelial carcinoma patients receiving PD-L1-targeting antibodies atezolizumab were used. The gene discussed is CD274; the disease is non-small cell lung carcinoma.